Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer

This study tests a combination of three drugs — nivolumab (immunotherapy), fluorouracil (chemotherapy), and interferon alpha 2B — for people with fibrolamellar hepatocellular carcinoma (FLHCC), a rare liver cancer that mainly affects young people without cirrhosis and for which few treatments exist. **You may be eligible if...** - You have a confirmed diagnosis of FLHCC (either by biopsy or prior documentation) - Your cancer cannot be surgically removed - You have measurable disease on imaging - Your overall health is good (ECOG 0-1, or Karnofsky 70+ for those under 18) - Your liver function, blood counts, and kidney function are within acceptable ranges - You have not previously received anti-PD-1 immunotherapy for FLHCC **You may NOT be eligible if...** - You have HIV, active hepatitis B, or active hepatitis C - You have had a liver transplant - You have a history of autoimmune disease (e.g., lupus, rheumatoid arthritis, Crohn's disease) - You have brain metastases or seizure disorders - You have had a heart attack, unstable chest pain, or significant heart disease in the last year - You are pregnant or breastfeeding - You are on anticoagulation therapy (blood thinners), high-dose steroids, or immune-suppressing drugs Talk to your doctor to see if this trial is right for you.